Table 2.

Synergistic consortia and single species with corresponding MOI ratios, NF-κB pathway activation compared to LPS-stimulated cells and FICI values.

Consortium 1				Single species from consortium 1
A. naeslundii MOIconsortia	S. sanguinis MOIconsortia	NF-κB pathway activation (%)	FICI	A. naeslundii MOIsingle	NF-κB pathway activation (%)	S. sanguinis MOIsingle	NF-κB pathway activation (%)
0.78	0.78	43.29	0.31	12.5	27.81	3.13	31.75
3.13	0.78	41.08	0.50
Consortium 2				Single species from consortium 2
S. sanguinis MOIconsortia	R. mucilaginosa MOIconsortia	NF-κB pathway activation (%)	FICI	S. sanguinis MOIsingle	NF-κB pathway activation (%)	R. mucilaginosa MOIsingle	NF-κB pathway activation (%)
0.78	0.01	47.51	0.31	3.13	31.75	0.20	44.96
0.78	0.05	47.02	0.50
Consortium 3				Single species from consortium 3
A. naeslundii MOIconsortia	R. mucilaginosa MOIconsortia	NF-κB pathway activation (%)	FICI	A. naeslundii MOIsingle	NF-κB pathway activation (%)	R. mucilaginosa MOIsingle	NF-κB pathway activation (%)
0.78	0.05	41.53	0.31	12.5	27.81	0.20	44.96
3.13	0.05	32.00	0.50
Consortium 5				Single species from consortium 5
A. naeslundii MOIconsortia	G. haemolysans MOIconsortia	NF-κB pathway activation (%)	FICI	A. naeslundii MOIsingle	NF-κB pathway activation (%)	G. haemolysans MOIsingle	NF-κB pathway activation (%)
3.13	0.20	42.88	0.27	12.5	27.81	12.5	30.56

MOI ratios were defined as synergistic if: < 50% NF-κB pathway activation compared to LPS-stimulated cells, p < 0.05 and FICI ≤ 0.5. n ≥ 3. Single species from the corresponding consortia with their mMOI_NF-κB and NF-κB pathway activation compared to LPS-stimulated cells are presented in the right column. The mMOI_NF-κB was defined as the lowest MOI with anti-inflammatory activity (i.e. < 50% NF-κB pathway activation compared to LPS-stimulated cells, p < 0,05, n ≥ 3).